George Peoples - Jul 1, 2024 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Role
Director
Signature
/s/ Andrew Jackson, Attorney-in-fact
Stock symbol
CLDI
Transactions as of
Jul 1, 2024
Transactions value $
$0
Form type
4
Date filed
7/11/2024, 04:53 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDI Non-Qualified Stock Options (right to buy) Award +30.9K 30.9K Jul 1, 2024 Common stock 30.9K $0.19 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on July 1, 2024 (the "Grant Date"), the Reporting Person was granted 30,904 non-qualified stock options (the "Options") at the exercise price of $0.193, which is the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/36 per month over three years, commencing on the Grant Date.

Remarks:

Exhibit 24 - Power of Attorney (previously filed as Exhibit 24 to Form 3 dated July 8, 2024.)